Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMO | Q99835 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 4/20 | 0.54 |
| ▸ | MAPT | P10636 | 2/20 | 0.54 |
| ▸ | CRHBP | P24387 | 1/20 | 0.54 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.54 |
| ▸ | NPSR1 | Q6W5P4 | 4/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.51 |
| ▸ | RAB9A | P51151 | 4/20 | 0.51 |
| ▸ | NPC1 | O15118 | 3/20 | 0.51 |
| ▸ | HTT | P42858 | 2/20 | 0.51 |
| ▸ | PAX8 | Q06710 | 2/20 | 0.51 |
| ▸ | XBP1 | P17861 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 3/20 | 0.48 |
| ▸ | BRAF | P15056 | 1/20 | 0.47 |
| ▸ | MPO | P05164 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9363470 | 0.86 | SMO (0.54) | SMOLMNAMAPTCRHBPCRHR2 | |
| SCHEMBL169569 | 0.85 | SMO (0.53) | SMOLMNAMAPTCRHBPCRHR2 | |
| SCHEMBL11381573 | 0.85 | NPSR1 (0.55) | SMOLMNAMAPTCRHBPCRHR2 | |
| SCHEMBL12770960 | 0.82 | MEN1 (0.68) | SMOLMNAMAPTNPSR1KDM4E | |
| SCHEMBL13719047 | 0.82 | HPGD (0.53) | SMOLMNAMAPTCRHBPCRHR2 | |
| SCHEMBL23402488 | 0.79 | NPC1 (0.54) | LMNAMAPTKDM4EHSD17B10MEN1 | |
| SCHEMBL11576596 | 0.79 | SMN1; SMN2 (0.58) | LMNAMAPTNPSR1KDM4EHSD17B10 | |
| SCHEMBL13602488 | 0.78 | SMN1; SMN2 (0.57) | SMOLMNAMAPTNPSR1KDM4E | |
| SCHEMBL14079404 | 0.78 | MPO (0.53) | SMOLMNAMAPTKDM4EHSD17B10 | |
| SCHEMBL12871680 | 0.78 | PTGS1 (0.46) | SMOLMNAMAPTCRHBPCRHR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7595399-B2 | Tyrosine derivatives | GENENTECH, INC. (US) | 2009-09-29 | — | — | US | disclosed |
| US-7595399-B2 | Tyrosine derivatives | GENENTECH, INC. (US) | 2009-09-29 | — | — | US | disclosed |
| US-7579479-B2 | Substituted acid derivatives useful as antidiabetic and antiobesity agents and method | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-08-25 | — | — | US | disclosed |
| US-7576117-B1 | Cyclic amine CCR3 antagonist | TEIJIN LIMITED (JP) | 2009-08-18 | — | — | US | disclosed |
| US-7576117-B1 | Cyclic amine CCR3 antagonist | TEIJIN LIMITED (JP) | 2009-08-18 | — | — | US | disclosed |
| US-20080075719-A1 | Method for Augmenting B Cell Depletion | GENENTECH, INC. (US) | 2008-03-27 | — | — | US | disclosed |
| US-20080075719-A1 | Method for Augmenting B Cell Depletion | GENENTECH, INC. (US) | 2008-03-27 | — | — | US | disclosed |
| US-7241780-B2 | Substituted acid derivatives useful as antidiabetic and antiobesity agents and method | BRISTOLS-MYERS SQUIBB COMPANY (US) | 2007-07-10 | — | — | US | disclosed |
| EP-1214292-B1 | TYROSINE DERIVATIVES | GENENTECH INC (US) | 2007-06-13 | — | — | EP | disclosed |
| US-20070015797-A1 | Substituted acid derivatives useful as antidiabetic and antiobesity agents and method | CHENG PETER T | 2007-01-18 | — | — | US | disclosed |
| WO-2005113003-A2 | METHOD FOR AUGMENTING B CELL DEPLETION | GENENTECH, INC. (US) | 2005-12-01 | — | — | WO | disclosed |
| WO-2003007959-A1 | QUINOXALINE DERIVATIVES WHICH HAVE PARP INHIBITORY ACTION | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2003-01-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080075719-A1 | Method for Augmenting B Cell Depletion | CD22, ITGAM, FCGR3B | SMO 3147/4885LMNA 2205/4885MAPT 4875/4885 |
| US-20070015797-A1 | Substituted acid derivatives useful as antidiabetic and antiobesity agents and method | GPR119, LIPC, ACACA | SMO 3350/4885LMNA 320/4885MAPT 4848/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.